4.7 Review

Evolution of Hydrogen Sulfide Therapeutics to Treat Cardiovascular Disease

Journal

CIRCULATION RESEARCH
Volume 123, Issue 5, Pages 590-600

Publisher

LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1161/CIRCRESAHA.118.311134

Keywords

animals; cardiovascular diseases; nitric oxide

Funding

  1. National Institutes of Health National Heart, Lung, and Blood Institute [5R01 HL116571, 5R01 HL092141]

Ask authors/readers for more resources

Hydrogen sulfide (H2S)a potent gaseous signaling moleculehas emerged as a critical regulator of cardiovascular homeostasis. H2S is produced enzymatically by 3 constitutively active endogenous enzymes in all mammalian species. Within the past 2 decades, studies administering H2S-donating agents and the genetic manipulation of H2S-producing enzymes have revealed multiple beneficial effects of H2S, including vasodilation, activation of antiapoptotic and antioxidant pathways, and anti-inflammatory effects. More recently, the heightened enthusiasm in this field has shifted to the development of novel H2S-donating agents that exert favorable pharmacological profiles. This has led to the discovery of novel H2S-mediated signaling pathways. This review will discuss recently developed H2S therapeutics, introduce signaling pathways that are influenced by H2S-dependent sulfhydration, and explore the dual-protective effect of H2S in cardiorenal syndrome.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available